Lung CancerNCT01152463
Sonography After Thoracic Surgery (SATS)
An observational study of Lung Cancer, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.
Trial summary
Lung cancer remains the leading cause of mortality from malignant diseases in both men and women worldwide. Following thoracic surgery and pulmonary resection, patients have a surgically induced pneumothorax / hydro-hemothorax and hence tube thoracostomy is necessary to drain the air and effusion. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer
- What is being tested?
- thoracic ultrasound
- Type of treatment
- Surgery or procedure
- How many people
- 120 participants
- Where
- 1 siteCanada
- Study dates
- Jun 2010to Dec 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: in-patient
Who may be able to join
- Patients undergoing elective, open and thoracoscopic thoracic surgery for any indication
Who cannot join
- Age < 18 years old
- Inability to consent for the study
- Chest wall anatomy precluding SATS
- Inability to sit upright
Trial locations and contacts
1 site in 1 country.
Canada1 site
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, H2L 4M1
About this study
Official title: Sonography After Thoracic Surgery - SATS (CT0011)
Lung cancer remains the leading cause of mortality from malignant diseases in both men and women worldwide. Following thoracic surgery and pulmonary resection, patients have a surgically induced pneumothorax / hydro-hemothorax and hence tube thoracostomy is necessary to drain the air and effusion. Due to this, patients must undergo post-operative chest x-ray (CXR) evaluations in order to evaluate the chest and make decisions regarding removal of chest tubes (CT) as well as for decisions regarding patient discharge. Thoracic Ultrasound (US) has been shown to be accurate at diagnosing pneumothorax and has been well-studied in the trauma population. To the investigators knowledge, there are currently no centers using thoracic US routinely in the post-operative setting following thoracic surgery.
Read the detailed description
Following thoracic surgery (both open and thoracoscopic) patients have a surgically induced pneumothorax and hence tube thoracostomy is needed to drain the air and effusion. Due to this, patients must undergo post operative chest x-ray (CXR) evaluations in order to evaluate the chest and make decisions regarding removal of chest tubes as well as for decisions regarding patient discharge. Following chest tube removal, most surgeons advocate further CXR evaluation to assure that no pneumothorax was introduced during removal of the tube.
Repetitive CXR evaluations are costly, inconvenient, expose the patient and healthcare worker to repetitive radiation, and require time. Surgeon-performed US could be performed as an adjunct to physical examination. This would allow surgeons to make decisions regarding chest tube removal during rounds, alleviate the need for most CXRs as well as decrease patient length of stay. The goals of this project is to: evaluate the reliability and accuracy of surgeon-performed US following thoracic surgery, and evaluate the potential improved convenience for patients and the healthcare system using surgeon-performed US.
US technology has traditionally been the domain of the radiologist; however, recently US has evolved into an important tool for the clinician, similar to the stethoscope of the past, which can be utilized in an organ and specialty specific manner. Users of US in clinical care on a daily basis for specialty specific indications are: cardiologists, gastroenterologists, anesthesiologists, OBGYN, trauma, breast, ENT, hepatobiliary, and colorectal surgeons. US technology has yet to find its place in the domain of the thoracic surgeon and in the diagnosis and treatment of pulmonary malignancy, although there are many potential important applications for its use. We believe that portable hand-held ultrasound may be the thoracic surgeon's stethoscope of the future.
Thoracic ultrasound has been shown to be accurate at diagnosing pneumothorax (sensitivity, specificity = 90%) and has been well studied in the trauma population (sensitivity 95%) , however, few studies have been done using thoracic ultrasound in the non-injured population . To our knowledge, there are currently no centers using thoracic ultrasound routinely in the post-operative setting following general thoracic surgery.
Buzzas et al. showed that surgeons and surgical residents performing focused abdominal sonography for the initial evaluation of trauma patients were able to correctly diagnose injuries as safely and accurately as radiologists . Sensitivity, specificity, accuracy and negative predictive values were not significantly different between the surgeon and radiologist groups.
This study will consist of a prospective evaluation of surgeon-performed US following thoracic surgery. CXR diagnosis of pneumothorax/pleural effusion will be taken to be the "gold standard" and US detection of pneumothorax/pleural effusion will be measured against CXR. Standard post-operative evaluation and management of these patients will be applied. Thoracic US evaluation of the chest will occur in the same time sequence as CXR for all patients enrolled in the study. The results of the US will be compared with the CXR findings. Proposed management decisions based on US will be compared with the actual management decision made by the surgeon based on the CXR finding.
The proposed project is a clinical feasibility and safety study concerning a new indication for surgeon performed ultrasound in general thoracic surgery. Surgeon performed ultrasound has recently become popular in the initial evaluation of the injured patient as well as for office-based visualization of cysts and masses. It is also being used to aid in biopsy of masses and attaining central venous access in the critical care setting.
We plan to evaluate surgeon performed ultrasound in the evaluation of post-operative pneumothorax and pleural effusion following thoracic surgery. Surgeon performed ultrasound will be compared to plain film CXR, which is considered the "gold standard". If the results of this study show that surgeon performed ultrasound is accurate and sensitive in the evaluation of post-operative thoracic surgery patients, ultrasound could replace CXR in the post-operative care of these patients.
Ultrasound evaluation of the pleural space by surgeons post-operatively would lead to decreased costs, length of stay and patient inconvenience. Surgeon-performed ultrasound could be used as an adjunct to physical examination during ward rounds. This would not only make the decisions regarding chest tube management possible during morning rounds, it would eliminate the cost of repeated CXRs. Following the initial cost of purchasing the ultrasound machine, performing the test on a daily basis would not cost anything. Furthermore, patients (with chest tubes) would no longer need to be transported to the radiology department in order to undergo proper evaluation of the pleural space.
There is a tremendous advantage to minimally invasive diagnostic and treatment strategies such as the ones described in this proposal to healthcare systems. By enabling early, rapid, and safe diagnostic and treatment strategies for patients, healthcare systems benefit from shorter hospital duration of stays, waiting times for procedures and costs. This is extremely attractive and important in a Canadian environment. This project will lead to enhanced process of care for lung cancer patients.
Hypotheses:
Bedside transthoracic ultrasonography is a simple, quick, reproducible, cost-effective and novel method of accurately evaluating post-operative thoracic surgery patients.
Objectives:
- Describe the surgeon and resident ability to learn and apply thoracic ultrasound to an inpatient population.
- Evaluate the reliability of surgeon-performed ultrasound following general thoracic surgery.
- Compare the criterion-related validity, and specifically the sensitivity, specificity, positive and negative predictive value of surgeon-performed ultrasound at diagnosing post-operative pneumothorax and effusion using chest x-ray as the criterion or "gold standard".
- Evaluate the marginal cost minimization associated with using surgeon performed ultrasound post thoracic surgery compared to conventional chest x-ray.
Study Design:
Prospective, cohort study design. Clinical Trial: Intervention - pleural US. All patients will receive post-operative pleural-based ultrasound during their follow-up care on the thoracic surgery ward.
Methods:
This study will consist of a prospective non-randomized evaluation of surgeon-performed ultrasound following thoracic surgery. All patients undergoing elective, open and thoracoscopic thoracic surgery for any indication at the CHUM - Hopital Notre Dame, Montreal, Quebec, Canada will be approached in an attempt to enrol them into the study. Patients will be enrolled and consented for the study by the treating physician during the pre-operative evaluation in the pre-operative clinic.
There are approximately 12 potential patients per week. Chest x-ray (CXR) diagnosis of pneumothorax will be taken to be the "gold standard" and ultrasound detection of pneumothorax will be measured against CXR. The sensitivity of ultrasound in diagnosing pneumothorax has been shown to be 95% .
A clinical nurse specialist will acquire all required data from interviews with each patient as well as from each patient's chart. He or she will enter all data into a prospective database specifically designed for the study. The nurse will also be responsible for assuring that the surgeons complete study case report forms correctly after each ultrasound evaluation. He or she will also record the results of all CXRs into the database.
Standard post-operative evaluation and management of these patients will be applied during the entire study. Chest x-rays will be ordered as usual and decisions regarding chest tube removal and management will be made based solely on CXR findings. Thoracic ultrasound evaluation of the chest will occur in the same time sequence as CXR for all patients enrolled in the study. A thoracic surgeon or senior surgical resident trained in thoracic ultrasound will perform all ultrasounds. The surgeon will record the outcome of his/her evaluation of the chest as a dichotomous variable (pneumothorax - YES/NO, pleural effusion - YES/NO) on a specialized study case report form. The surgeon will also record a management decision on the study report form (the management that he/she would have undertaken if he/she was acting on the ultrasound finding alone). The results of the ultrasound will be compared with the CXR findings (as reported by staff radiologists). Proposed management decisions based on ultrasound will be compared with the actual management decision made by the surgeon based on the CXR finding. The radiologist will be blind with respect to the surgeon's ultrasound assessment and vice-versa.
Learning Phase During the first two weeks of the study, surgeons and residents will practice the ultrasound techniques on 24 patients. The results of their findings will be compared to CXR and will be evaluated in order to assess the learning curve for this technique. During this phase of the study, any discrepancy between the surgical staff's findings and the CXR will be reported to the staff during the same day to provide feedback that will enhance the learning process. After the surgical staff reviews the CXR, he or she will then re-evaluate the patient using the ultrasound machine in order to learn from his or her mistake. Management decisions regarding patient care based on the ultrasound will not be recorded during the "learning phase" of the study.
Assessment Phase Following the learning phase, the assessment study will commence. During this phase, all patients enrolled in the study will undergo ultrasound evaluation of the pleural space every time a CXR is ordered in the post-operative period. The ultrasound for each patient will be conduced by two different surgeons that will be selected randomly or pseudo-randomly based on availability.
This phase of the study will be conducted in order to define the reliability of ultrasound in diagnosing pneumothorax/pleural effusion, as well as the ability of ultrasound to be used as the sole decision-making diagnostic test following general thoracic surgery.
Reliability and specifically inter-rater reliability will be assessed by the degree of agreement of the ultra-sound results recorded by the two surgeons. The kappa statistic will be used to assess the degree of agreement with a minimal kappa level of 70%.
Sensitivity, specificity, positive predictive value, negative predictive value, overall accuracy and likelihood ratios will be computed for the surgeon-ultrasound against the CXR. Each surgeon's observation will be considered as an independent record, thus removing the complication of disagreement between surgeons and possible confounding. The psychometric properties listed above will be estimated as crude values. However, subgroup analyses and logistic regression will evaluate the impact of surgeon/assessor, learning curve slope of the surgeon, difficulty of case as assessed by the radiologist on the accuracy and the likelihood of false negative and false positive results.
Marginal costs differences between the surgeon performed ultrasound and CXR will be based on an overall risk-benefit assessment that will take into account training requirements, accuracy and costs of facilities as well as physician services. Cost assessment will take into account the management of potential false negative and false positive results.
- Conditions
- Lung Cancer
- Being tested
- thoracic ultrasound
- Keywords
- thoracic ultrasound (US), post-op care, pneumothorax, pleural effusion
- Medical subject headings
- Lung Neoplasms, Pneumothorax, Pleural Effusion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
thoracic ultrasoundProcedure or surgery
daily thoracic ultrasound evaluation of the chest
What is being measured
The primary outcome is the main question the study is designed to answer.
US post thoracic surgery will be measured against CXR in the detection of pneumothorax/pleural effusion. Decisions will be made regarding chest tube removal during rounds, alleviate the need for more CXR as well as decrease patient length of stay.
Surgeon performed ultrasound will be compared to plain film CXR, which is considered the "gold standard". If the result of this study show that surgeon performed US is accurate and sensitive in the evaluation of post-operative thoracic surgery patients, US could replace CXR in the post-operative care of these patients
Measured: on a daily basis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2010 (estimated)
- Study startJun 2010
- Primary completionSep 2010
- Study completionDec 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
- Sponsor type
- University, hospital or other
- Collaborators
- Fonds de la Recherche en Santé du Québec, Canada Foundation for Innovation, Centre de Recherche du Centre Hospitalier de l'Université de Montréal
- Responsible party
- Sponsor
- Investigators
- Moishe Liberman, MD, PhD, Principal investigator, Centre hospitalier de l'Université de Montréal (CHUM)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01152463
- Sponsor's protocol ID
- CE 10.041
- Status last verified
- Jun 2010
- First submitted
- 2 Jun 2010
- Last updated
- 22 Jun 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sonography After Thoracic Surgery - SATS (CT0011)
- ClinicalTrials.gov ID
- NCT01152463
- Acronym / sponsor ID
- CE 10.041
- Conditions
- Lung Cancer
- Keywords
- thoracic ultrasound (US), post-op care, pneumothorax, pleural effusion
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)University, hospital or other
- Collaborators
- Fonds de la Recherche en Santé du Québec, Canada Foundation for Innovation, Centre de Recherche du Centre Hospitalier de l'Université de Montréal
- Study start
- Jun 2010
- Primary completion
- Sep 2010 (actual)
- Study completion
- Dec 2010 (actual)
- First posted
- 29 Jun 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lung cancer remains the leading cause of mortality from malignant diseases in both men and women worldwide. Following thoracic surgery and pulmonary resection, patients have a surgically induced pneumothorax / hydro-hemothorax and hence tube thoracostomy is necessary to drain the air and effusion. Due to this, patients must undergo post-operative chest x-ray (CXR) evaluations in order to evaluate the chest and make decisions regarding removal of chest tubes (CT) as well as for decisions regarding patient discharge. Thoracic Ultrasound (US) has been shown to be accurate at diagnosing pneumothorax and has been well-studied in the trauma population. To the investigators knowledge, there are currently no centers using thoracic US routinely in the post-operative setting following thoracic surgery.
Detailed description
Following thoracic surgery (both open and thoracoscopic) patients have a surgically induced pneumothorax and hence tube thoracostomy is needed to drain the air and effusion. Due to this, patients must undergo post operative chest x-ray (CXR) evaluations in order to evaluate the chest and make decisions regarding removal of chest tubes as well as for decisions regarding patient discharge. Following chest tube removal, most surgeons advocate further CXR evaluation to assure that no pneumothorax was introduced during removal of the tube.
Repetitive CXR evaluations are costly, inconvenient, expose the patient and healthcare worker to repetitive radiation, and require time. Surgeon-performed US could be performed as an adjunct to physical examination. This would allow surgeons to make decisions regarding chest tube removal during rounds, alleviate the need for most CXRs as well as decrease patient length of stay. The goals of this project is to: evaluate the reliability and accuracy of surgeon-performed US following thoracic surgery, and evaluate the potential improved convenience for patients and the healthcare system using surgeon-performed US.
US technology has traditionally been the domain of the radiologist; however, recently US has evolved into an important tool for the clinician, similar to the stethoscope of the past, which can be utilized in an organ and specialty specific manner. Users of US in clinical care on a daily basis for specialty specific indications are: cardiologists, gastroenterologists, anesthesiologists, OBGYN, trauma, breast, ENT, hepatobiliary, and colorectal surgeons. US technology has yet to find its place in the domain of the thoracic surgeon and in the diagnosis and treatment of pulmonary malignancy, although there are many potential important applications for its use. We believe that portable hand-held ultrasound may be the thoracic surgeon's stethoscope of the future.
Thoracic ultrasound has been shown to be accurate at diagnosing pneumothorax (sensitivity, specificity = 90%) and has been well studied in the trauma population (sensitivity 95%) , however, few studies have been done using thoracic ultrasound in the non-injured population . To our knowledge, there are currently no centers using thoracic ultrasound routinely in the post-operative setting following general thoracic surgery.
Buzzas et al. showed that surgeons and surgical residents performing focused abdominal sonography for the initial evaluation of trauma patients were able to correctly diagnose injuries as safely and accurately as radiologists . Sensitivity, specificity, accuracy and negative predictive values were not significantly different between the surgeon and radiologist groups.
This study will consist of a prospective evaluation of surgeon-performed US following thoracic surgery. CXR diagnosis of pneumothorax/pleural effusion will be taken to be the "gold standard" and US detection of pneumothorax/pleural effusion will be measured against CXR. Standard post-operative evaluation and management of these patients will be applied. Thoracic US evaluation of the chest will occur in the same time sequence as CXR for all patients enrolled in the study. The results of the US will be compared with the CXR findings. Proposed management decisions based on US will be compared with the actual management decision made by the surgeon based on the CXR finding.
The proposed project is a clinical feasibility and safety study concerning a new indication for surgeon performed ultrasound in general thoracic surgery. Surgeon performed ultrasound has recently become popular in the initial evaluation of the injured patient as well as for office-based visualization of cysts and masses. It is also being used to aid in biopsy of masses and attaining central venous access in the critical care setting.
We plan to evaluate surgeon performed ultrasound in the evaluation of post-operative pneumothorax and pleural effusion following thoracic surgery. Surgeon performed ultrasound will be compared to plain film CXR, which is considered the "gold standard". If the results of this study show that surgeon performed ultrasound is accurate and sensitive in the evaluation of post-operative thoracic surgery patients, ultrasound could replace CXR in the post-operative care of these patients.
Ultrasound evaluation of the pleural space by surgeons post-operatively would lead to decreased costs, length of stay and patient inconvenience. Surgeon-performed ultrasound could be used as an adjunct to physical examination during ward rounds. This would not only make the decisions regarding chest tube management possible during morning rounds, it would eliminate the cost of repeated CXRs. Following the initial cost of purchasing the ultrasound machine, performing the test on a daily basis would not cost anything. Furthermore, patients (with chest tubes) would no longer need to be transported to the radiology department in order to undergo proper evaluation of the pleural space.
There is a tremendous advantage to minimally invasive diagnostic and treatment strategies such as the ones described in this proposal to healthcare systems. By enabling early, rapid, and safe diagnostic and treatment strategies for patients, healthcare systems benefit from shorter hospital duration of stays, waiting times for procedures and costs. This is extremely attractive and important in a Canadian environment. This project will lead to enhanced process of care for lung cancer patients.
Hypotheses:
Bedside transthoracic ultrasonography is a simple, quick, reproducible, cost-effective and novel method of accurately evaluating post-operative thoracic surgery patients.
Objectives:
- Describe the surgeon and resident ability to learn and apply thoracic ultrasound to an inpatient population.
- Evaluate the reliability of surgeon-performed ultrasound following general thoracic surgery.
- Compare the criterion-related validity, and specifically the sensitivity, specificity, positive and negative predictive value of surgeon-performed ultrasound at diagnosing post-operative pneumothorax and effusion using chest x-ray as the criterion or "gold standard".
- Evaluate the marginal cost minimization associated with using surgeon performed ultrasound post thoracic surgery compared to conventional chest x-ray.
Study Design:
Prospective, cohort study design. Clinical Trial: Intervention - pleural US. All patients will receive post-operative pleural-based ultrasound during their follow-up care on the thoracic surgery ward.
Methods:
This study will consist of a prospective non-randomized evaluation of surgeon-performed ultrasound following thoracic surgery. All patients undergoing elective, open and thoracoscopic thoracic surgery for any indication at the CHUM - Hopital Notre Dame, Montreal, Quebec, Canada will be approached in an attempt to enrol them into the study. Patients will be enrolled and consented for the study by the treating physician during the pre-operative evaluation in the pre-operative clinic.
There are approximately 12 potential patients per week. Chest x-ray (CXR) diagnosis of pneumothorax will be taken to be the "gold standard" and ultrasound detection of pneumothorax will be measured against CXR. The sensitivity of ultrasound in diagnosing pneumothorax has been shown to be 95% .
A clinical nurse specialist will acquire all required data from interviews with each patient as well as from each patient's chart. He or she will enter all data into a prospective database specifically designed for the study. The nurse will also be responsible for assuring that the surgeons complete study case report forms correctly after each ultrasound evaluation. He or she will also record the results of all CXRs into the database.
Standard post-operative evaluation and management of these patients will be applied during the entire study. Chest x-rays will be ordered as usual and decisions regarding chest tube removal and management will be made based solely on CXR findings. Thoracic ultrasound evaluation of the chest will occur in the same time sequence as CXR for all patients enrolled in the study. A thoracic surgeon or senior surgical resident trained in thoracic ultrasound will perform all ultrasounds. The surgeon will record the outcome of his/her evaluation of the chest as a dichotomous variable (pneumothorax - YES/NO, pleural effusion - YES/NO) on a specialized study case report form. The surgeon will also record a management decision on the study report form (the management that he/she would have undertaken if he/she was acting on the ultrasound finding alone). The results of the ultrasound will be compared with the CXR findings (as reported by staff radiologists). Proposed management decisions based on ultrasound will be compared with the actual management decision made by the surgeon based on the CXR finding. The radiologist will be blind with respect to the surgeon's ultrasound assessment and vice-versa.
Learning Phase During the first two weeks of the study, surgeons and residents will practice the ultrasound techniques on 24 patients. The results of their findings will be compared to CXR and will be evaluated in order to assess the learning curve for this technique. During this phase of the study, any discrepancy between the surgical staff's findings and the CXR will be reported to the staff during the same day to provide feedback that will enhance the learning process. After the surgical staff reviews the CXR, he or she will then re-evaluate the patient using the ultrasound machine in order to learn from his or her mistake. Management decisions regarding patient care based on the ultrasound will not be recorded during the "learning phase" of the study.
Assessment Phase Following the learning phase, the assessment study will commence. During this phase, all patients enrolled in the study will undergo ultrasound evaluation of the pleural space every time a CXR is ordered in the post-operative period. The ultrasound for each patient will be conduced by two different surgeons that will be selected randomly or pseudo-randomly based on availability.
This phase of the study will be conducted in order to define the reliability of ultrasound in diagnosing pneumothorax/pleural effusion, as well as the ability of ultrasound to be used as the sole decision-making diagnostic test following general thoracic surgery.
Reliability and specifically inter-rater reliability will be assessed by the degree of agreement of the ultra-sound results recorded by the two surgeons. The kappa statistic will be used to assess the degree of agreement with a minimal kappa level of 70%.
Sensitivity, specificity, positive predictive value, negative predictive value, overall accuracy and likelihood ratios will be computed for the surgeon-ultrasound against the CXR. Each surgeon's observation will be considered as an independent record, thus removing the complication of disagreement between surgeons and possible confounding. The psychometric properties listed above will be estimated as crude values. However, subgroup analyses and logistic regression will evaluate the impact of surgeon/assessor, learning curve slope of the surgeon, difficulty of case as assessed by the radiologist on the accuracy and the likelihood of false negative and false positive results.
Marginal costs differences between the surgeon performed ultrasound and CXR will be based on an overall risk-benefit assessment that will take into account training requirements, accuracy and costs of facilities as well as physician services. Cost assessment will take into account the management of potential false negative and false positive results.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- in-patient
Key inclusion criteria (1 listed)
- Patients undergoing elective, open and thoracoscopic thoracic surgery for any indication
Key exclusion criteria (4 listed)
- Age < 18 years old
- Inability to consent for the study
- Chest wall anatomy precluding SATS
- Inability to sit upright
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| thoracic ultrasounddaily thoracic ultrasound evaluation of the chest | Procedure or surgery | – |
Primary outcome
US post thoracic surgery will be measured against CXR in the detection of pneumothorax/pleural effusion. Decisions will be made regarding chest tube removal during rounds, alleviate the need for more CXR as well as decrease patient length of stay.
Time frame: on a daily basis
Surgeon performed ultrasound will be compared to plain film CXR, which is considered the "gold standard". If the result of this study show that surgeon performed US is accurate and sensitive in the evaluation of post-operative thoracic surgery patients, US could replace CXR in the post-operative care of these patients
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2012.
Related trials for Lung Cancer
Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Lung Neoplasms, Neoadjuvant Therapy
Not yet recruitingPhase 3
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
RecruitingObservational study
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
Lung Cancer
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Moishe Liberman, MD, PhD principal investigator
Centre hospitalier de l'Université de Montréal (CHUM)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jun 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
US post thoracic surgery will be measured against CXR in the detection of pneumothorax/pleural effusion. Decisions will be made regarding chest tube removal during rounds, alleviate the need for more CXR as well as decrease patient length of stay. (time frame: on a daily basis). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2012.